Posters

Is it OK to delay phaco post-op visit?

Poster Details

First Author: S.Al Zaaidi SAUDI ARABIA

Co Author(s):    T. Bin Dakhil   A. AlRajhi                 

Abstract Details

Purpose:

To review cases underwent phacoemulsification and not seen in the fist day post surgery looking for early postoperative complications.

Setting:

Tertiary care center, utilizing day case surgery unit, Prince Sultan Medical Military City, Riyadh, KSA

Methods:

Retrospective review of all 28 cases not seen in the first day post cataract phacoemulsification  under topical anesthesia by single anterior segment consultant (S.Z) in weekends between 9/2018 & 2/2019. All patients received intracamral cefuroxime 1mg/0.1ml. Postoperatively, all received prednisolone drops and moxifloxacin drops.. The chart review included the first 2 visits for follow-ups (2 days up to 6 weeks post op). The data were collected from operative report, 2 post-operative visits. Data collected included patient's symptoms, visual acuity, intraocular pressure (IOP), status of the cornea & corneal wounds, anterior chamber reaction, IOL position and other comments or findings reported.

Results:

All patients had a standardized surgical setting. 17 seen 2nd post-op(60.7%) and 11 (39.3%) seen in the 3rd day. None of the patients reported serious symptoms. In the first visit, 25% achieved VA 6/7.5 while >53% scored 6/12 or better while all improved except one with aphakia. None had high IOP (9-18 mmHg). None of the patients had corneal edema, wound leak/gaping or burn. 3 patients had 1+ cells or more (10.7%) while the rest were quite to trace cells. IOL  in place (97%) in all except the one who underwent Phaco + anterior vitrectomy.

Conclusions:

First Phacoemulsification follow-up visit might be delayed in none complicated cases up-to 3 days in uneventful surgeries performed by an experience surgeon. Furthermore, such protocol must include easy & 24 hours accessibility to service and proper instructions to the patients about serious symptoms. We need further studies with larger population.

Financial Disclosure:

None